ASX ANNOUNCEMENT

Notification under section 708A(5)(e) of the *Corporations Act 2001 (Cth)*

Wellington, NZ, 27 September 2018: Volpara Health Technologies ("Volpara" or "Company"; ASX: VHT) gives this notices in accordance with section 708A(5)(e) of the *Corporations Act 2001 (Cth)* (**Corporations Act**).

On 27 September 2018, Volpara issued 26,000 new fully paid ordinary shares as a result of the exercise of options under the Company's Employee Share Option Plan (ESOP).

Volpara advises that:

1. The shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act and without a Product Disclosure Statement for the shares being prepared;

2. This notice is being given under section 708A(5)(e) of the Corporations Act;

3. As a disclosing entity, Volpara is subject to regular reporting and disclosure obligations;

4. As at the date of this notice, Volpara has complied with:

   (i) The provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
   (ii) Section 674 of the Corporations Act; and

5. As at the date of this notice, there is no excluded information of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act that is required to be disclosed by the Company under 708A(6)(e) of the Corporations Act.

For and on behalf of the Board.

Craig Hadfield

Chief Financial Officer and Company Secretary

For further information, please contact:

Ralph Highnam, CEO
Volpara Health Technologies
ralph.highnam@volparasolutions.com
t: +64 21 149 0541

Kyahn Williamson
WE Buchan
kwilliamson@we-buchan.com
t: +61 3 9866 4722

About Volpara Health Technologies Limited (ASX: VHT)

VHT is a MedTech SaaS company founded in 2009 on research originally conducted at Oxford University. VHT's clinical applications for screening clinics provide feedback on breast density, compression, dose and quality, while its enterprise-wide software, VolparaEnterprise, provides role specific dashboards and wide-ranging benchmarking analytics to help clinics manage their business more efficiently.

VHT's technology and services have been used by customers and/or research projects in 36 countries and are supported by numerous patents, trademarks and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A$40 million, including A$20 million in April and May 2018. VHT is based in Wellington, New Zealand.

For more information, visit www.volparasolutions.com